December 14, 2021
4 min watch
Save
VIDEO: Early data on novel CAR T-cell targets, combination therapy tops ASH virtual meeting
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Saad Usmani, MD, division chief of plasma cell disorders and director of clinical research in hematologic malignancies at Levine Cancer Institute/Atrium Health, offers insights regarding abstracts on developments in chimeric antigen receptor T-cell therapy at ASH Annual Meeting and Expo. Topics included a CAR-T 21 data update, exploratory studies looking at combining the fully human BCMA-directed CAR-T with a gamma secretase inhibitor, a larger study on allogeneic CAR T-cell therapy for multiple myeloma, and a first of its kind study on MCARH 109 in patients with relapse refractory multiple myeloma.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Dr. Usmani reports grants and personal fees from Amgen, Celgene, GSK, Janssen, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDX, and Takeda, personal fees from Abbvie and MundiPharma, and grants from BMS and Pharmacyclics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.